PMID- 23124547
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20211021
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Dec
TI  - Clinical significance of human leukocyte antigen loss and melanoma-associated 
      antigen 4 expression in smokers of non-small cell lung cancer patients.
PG  - 997-1004
LID - 10.1007/s10147-012-0491-8 [doi]
AB  - BACKGROUND: Melanoma-associated antigen-A4 (MAGE-A4) is one of the candidates for 
      a target of immunotherapy and is expressed in non-small cell lung cancer (NSCLC). 
      However, tumors sometimes lose human leukocyte antigen (HLA) class I expression, 
      and tumor-specific T cells cannot eliminate the tumor with loss of HLA. However, 
      the relationship between MAGE-A4 expression and HLA loss has remained unclear. 
      METHODS: Among 363 NSCLC patients who consecutively underwent curative surgery, 
      187 cases whose material could be analyzed were reviewed. The expression of HLA 
      class I molecules was assessed by immunohistochemical staining. The expression of 
      MAGE-A4 was analyzed by RT-PCR. RESULTS: Seventy-seven tumors expressed HLA 
      normally; however, 110 tumors lost HLA. The proportion of patients with a smoking 
      habit and expressing the MAGE-A4 gene in patients with HLA loss was higher than 
      those with HLA expression (p = 0.04 and 0.028, respectively). Five-year overall 
      survival (OS) rate in the patients expressing MAGE-A4 but with loss of HLA was 
      52.4 %, and OS was significantly poorer than their counterparts (74.0 %, 
      p = 0.036). Multivariate analysis indicated that advanced stage or history of 
      smoking and HLA loss was an independently poor prognostic predictor of OS in 
      NSCLC (p < 0.01 and p = 0.04, respectively). CONCLUSION: HLA class I loss in 
      NSCLC was related to smoking history and MAGE-A4 expression of tumors. HLA class 
      I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in 
      NSCLC.
FAU - Baba, Tetsuro
AU  - Baba T
AD  - Department of Surgery II, School of Medicine, University of Occupational and 
      Environmental Health, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu, 807-8555, Japan, 
      t-baba@med.uoeh-u.ac.jp.
FAU - Shiota, Hironobu
AU  - Shiota H
FAU - Kuroda, Koji
AU  - Kuroda K
FAU - Shigematsu, Yoshiki
AU  - Shigematsu Y
FAU - Ichiki, Yoshinobu
AU  - Ichiki Y
FAU - Uramoto, Hidetaka
AU  - Uramoto H
FAU - Hanagiri, Takeshi
AU  - Hanagiri T
FAU - Tanaka, Fumihiro
AU  - Tanaka F
LA  - eng
PT  - Journal Article
DEP - 20121103
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 0 (MAGEA4 protein, human)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/*biosynthesis/genetics/immunology
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/immunology/mortality/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - HLA Antigens/*biosynthesis/immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*biosynthesis/genetics/immunology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Smoking/adverse effects
MH  - Survival Analysis
EDAT- 2012/11/06 06:00
MHDA- 2014/08/19 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/07/10 00:00 [received]
PHST- 2012/10/12 00:00 [accepted]
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
AID - 10.1007/s10147-012-0491-8 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2013 Dec;18(6):997-1004. doi: 10.1007/s10147-012-0491-8. Epub 
      2012 Nov 3.